Back to News
Market Impact: 0.48
Grail rallies as FDA staff flags no major concerns for multi-cancer test
Source: reuters.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
FDA staff reviewers raised no major concerns regarding the accuracy or safety of Grail's blood test designed to detect more than 50 cancers. Grail shares surged 35% on Monday, reflecting increased confidence in the test's regulatory prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
GRAL0.90
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Grail rallies as FDA staff flags no major concerns for multi-cancer test
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros